The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
More biotechs test the third way to market
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?